The first treatment of its kind for metastatic NSCLC, Optune Lua is approved for use concurrently with PD-1/PD-L1 inhibitors or docetaxel in adult patients with metastatic NSCLC who progressed on or ...
Novocure today announced positive findings from a study of its tumor treating fields (TTFields) in metastatic pancreatic ...
Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE Mark ...
Hosted on MSN
Novocure outlines expansion plans for lung cancer treatment and regulatory milestones in 2025
Executive Chairman Bill Doyle highlighted the company’s transition to a multi-indication oncology company, emphasizing the regulatory and commercial advancements. He announced the European CE Mark ...
What is Optune Gio ® approved to treat? Optune Gio is a wearable, portable, FDA-approved device indicated to treat a type of brain cancer called glioblastoma multiforme (GBM) in adult patients 22 ...
ROOT, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ:NVCR) today announced the reimbursement and availability of Optune together with temozolomide (TMZ) for the treatment of adult patients with newly ...
Data Supporting the Optune Pax FDA Approval PANOVA-3 was an international, prospective, randomized, open-label, controlled Phase 3 clinical trial designed to evaluate the use of Optune Pax ...
Novocure NVCR recently announced that Japan’s Ministry of Health, Labour and Welfare has approved reimbursement for Optune Lua through the country’s National Health Insurance program. In Japan, Optune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results